Track CalAmp Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CalAmp Corp. CAMP · Stock Open CalAmp Corp. in new tab

3.80 USD
EPS
-2.11
P/B
2.46
ROE
-146.12
Beta
0.28
Target Price
10.22 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-2.11
Book Value1.71
Price to Book2.46
Debt/Equity6.02
% Insiders9.651%
Growth
Revenue Growth1.39%
Estimates
Forward P/E-5.24
Forward EPS-0.80
Target Mean Price10.22

DCF valuation

Model fair value for CalAmp Corp. (CAMP)
Result
Sign in to run the valuation for CAMP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 10.22 USD (low 6.00, high 15.00) · as of 12 Nov 2026
Low 6.00
Mean 10.22
High 15.00
Price 3.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CalAmp Corp. Logo CalAmp Corp. Analysis (CAMP)

United States Information Technology Official Website Stock

Is CalAmp Corp. a good investment? CalAmp Corp. (CAMP) is currently trading at 3.80 USD. Market analysts have a consensus price target of 10.22 USD. This suggests a potential upside from current levels.

Earnings Schedule: CalAmp Corp. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -0.80.

Investor FAQ

Does CalAmp Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is CalAmp Corp.?

CalAmp Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -2.11.

Company Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Exchange Ticker
NMS (United States) CAMP
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 25, 1996 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion